Doxycycline in lymphangioleiomyomatosis: not all questions are answered

From the authors: We are grateful to B.G. Baldi and colleagues for their interest in our paper [1]. We agree that based upon our own, as well as the author's, data that doxycycline cannot currently be recommended as a therapy to reduce a decline in lung function in patients with lymphangioleiomyomatosis (LAM). As the authors pointed out, in our randomised placebo-controlled study, the two groups had slightly differing baseline lung-function values, which may have led to …